Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value
By Nick Paul Taylor,
BioSpace
| 03. 14. 2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene autotemcel) when the Medicines and Healthcare products Regulatory Agency approved the treatment in November 2023. However, regulatory approval is just the first of two key steps to reaching patients in the U.K. Vertex must also show the therapy is cost-effective before it can be used routinely by the National Health Service (NHS).
The U.K. National Institute for Health and Care Excellence (NICE) recommended against the use of Casgevy in sickle cell disease in draft guidance. The therapy has a list price of $2.2 million in the U.S. but NICE’s guidance says the U.K. price is “commercial in confidence.” Vertex’s justification for the cost rests on the potential for a one-time treatment with Casgevy to provide a functional cure for sickle cell disease.
Currently, NICE’s cost-effectiveness estimate for Casgevy exceeds the threshold it normally views as a good use of the...
Related Articles
By Osagie K. Obasogie, L.A. Review of Books | 04.17.2024
When Robert G. Edwards won the Nobel Prize in Physiology or Medicine in 2010 for developing in vitro fertilization (IVF) decades earlier in 1978, many members of the scientific community sighed in relief. This honor, they felt, was long...
By Lauren Quinn, Hazlitt | 05.01.2024
“It hurt,” my friend told me. “They don’t tell you that it hurts.”
Her voice came heavy through my headphones as I scrubbed the dinner dishes. “Like, I could feel the needle going through all the layers—skin, fat, muscle—and I could...
By Emi Nietfeld, Slate | 05.07.2024
Amy Yin always envisioned having at least two daughters. She spent her 20s working as an engineer and founding a startup in San Francisco. When she wasn’t working, vacationing with friends, and spoiling her cats, Amy dedicated herself to...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...